(ARAY) Accuray Incorporated Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(ARAY) Accuray Incorporated Complete Analysis Pack
Accuray’s Business Model Canvas: A Clear Strategic Snapshot
Unlock the full strategic blueprint behind Accuray Incorporated’s business model. This concise Business Model Canvas shows how the company creates value in medical technology, serves key customer segments, and supports growth through partnerships and innovation. Perfect for investors, analysts, and strategists who want the complete picture.
Partnerships
Global distributors
In FY2025, Accuray reported about $459 million in revenue, and distributors remained key in international markets where direct coverage is less efficient. They localize sales and market access across Europe, the Middle East, India, Africa, Japan, China, and Asia Pacific.
U.S. sales agents
Accuray uses U.S. sales agents with its direct team to reach hospitals and treatment centers faster. With a global installed base of more than 1,000 systems across 100+ countries, this added local coverage helps widen lead flow and speed commercial access.
Group purchasing organizations
U.S. group purchasing organizations, which cover about 96% of U.S. hospitals, help Accuray Incorporated reach healthcare buyers and lower procurement friction for capital equipment and service contracts. These groups can shape vendor shortlists and pricing, so access through them can speed purchasing decisions in a market where U.S. healthcare providers spend hundreds of billions of dollars each year on purchased services and equipment.
Component and supply partners
Accuray relies on component and supply partners for precision hardware, electronics, and regulated manufacturing inputs that keep its 1,000+ installed systems running worldwide. For radiosurgery platforms, continuity matters: a delay in sourced parts can hit both production and service uptime.
- Precision parts and electronics are critical
- Supply continuity protects production
- Service uptime depends on stable sourcing
These partners also help Accuray meet quality and regulatory standards across complex medical systems.
Clinical and hospital collaborators
Hospitals, cancer centers, and clinical users help Accuray validate systems, tune treatment planning, and speed therapy adoption; that feedback also feeds product upgrades, installation, training, and post-sale support. In FY2025, Accuray’s operating model still depended on these sites to convert clinical proof into recurring system use and service revenue.
- Validates clinical performance
- Improves workflow adoption
- Supports installation and training
- Strengthens post-sale success
Accuray’s Partner Network Powered Global Revenue and Reach
In FY2025, Accuray’s key partners were distributors, U.S. sales agents, group purchasing organizations, component suppliers, and clinical sites. These links supported about $459 million in revenue, helped access 1,000+ installed systems in 100+ countries, and reduced buying and service friction for complex radiation therapy platforms.
| Partner | Role | FY2025 signal |
|---|---|---|
| Distributors | International reach | 100+ countries |
What is included in the product
Detailed Word Document
A concise, real-world Business Model Canvas outlining Accuray’s customers, value proposition, channels, and revenue model.
Customizable Excel Spreadsheet
Helps relieve business-model confusion by giving a clear, editable snapshot of Accuray Incorporated’s strategy.
Reference Sources
Provides a trusted source trail for Accuray Incorporated, making key claims easier to verify and decisions faster to defend.
Activities
System design and development
Accuray’s key activity is system design and development for CyberKnife and TomoTherapy, where R and D keeps image guidance, treatment precision, and clinical capability moving forward. In fiscal 2025, the company continued to invest in product engineering and software upgrades to support a global installed base of more than 1,000 radiation therapy systems.
Manufacturing and production
Accuray Incorporated’s manufacturing and production turn complex tumor-treatment systems into shippable units, so every build must clear strict FDA and global quality checks. In FY2025, the company’s scale was about $458 million in annual revenue, and production timing directly shaped delivery, reliability, and field performance.
Clinical software and planning development
Accuray builds clinical software like Precision Planning and iDMS to connect planning, dose calculation, and delivery in one workflow. In fiscal 2025, the company reported about $458 million in net revenue, and software capability remained a core product differentiator.
Sales and market access
Accuray sells mainly through direct sales to hospitals and specialty cancer centers, with agents and distributors in selected markets. Market access is a key activity because capital equipment buys hinge on clinical proof, reimbursement fit, and site-level adoption, so each sale often needs long procurement and training cycles.
- Direct hospital sales drive core revenue.
- Agents expand reach in select regions.
- Market access speeds capital equipment adoption.
Post-sale support and services
In FY2025, Accuray supported a global installed base of 1,000+ systems with installation, training, customer support, and professional services. That long-tail service model helps hospitals deploy systems safely and keep uptime high in a clinical setting, where even short delays can disrupt care.
- Installation and training speed go-live
- Support lowers clinical risk
- Recurring services deepen customer ties
Accuray Builds Growth on 1,000+ Systems and $457.6M Revenue
Accuray’s key activities are R and D, system manufacturing, and clinical software development for CyberKnife and TomoTherapy, with FY2025 revenue of $457.6 million and an installed base above 1,000 systems. It also runs direct sales, installation, training, and service support, which keep hospitals buying and using its radiation therapy platforms.
| Key activity | FY2025 data |
|---|---|
| Revenue | $457.6 million |
| Installed base | 1,000+ systems |
| Core focus | R and D, manufacturing, software, service |
What You See Is What You Get
Business Model Canvas
This preview shows the actual Accuray Incorporated Business Model Canvas you’ll receive after purchase, not a sample or mockup. Every section, layout, and detail is taken directly from the final document. Once you buy, you’ll unlock the exact same file, ready to download, edit, and use right away.
Resources
CyberKnife platform
The CyberKnife System is one of Accuray Incorporated’s core assets: a robotic platform for stereotactic radiosurgery and stereotactic body radiation therapy that can treat tumors outside the brain in 1 to 5 sessions. Its precision, with sub-millimeter targeting, makes it a key resource for hospitals aiming to grow advanced oncology cases.
Radixact and TomoTherapy systems
Radixact and TomoTherapy are Accuray Incorporated’s core assets, with more than 1,000 systems installed worldwide. Their integrated planning and delivery platform supports highly precise radiation therapy, helping expand use cases in both routine and complex cancer care.
Software and data systems
In FY2025, Accuray generated about $413 million in revenue, and its planning and data systems sit at the core of how CyberKnife and TomoTherapy work together. These software tools connect treatment planning, delivery, and patient data, helping Accuray differentiate beyond hardware alone.
Regulatory and clinical expertise
Regulatory and clinical expertise is a core moat for Accuray Incorporated: getting radiotherapy systems cleared, validated, and kept safe needs deep FDA, CE, engineering, and clinician know-how. In FY2025, Accuray reported $458.6 million revenue, and that scale depends on strict quality systems and approval discipline that are hard to copy.
- Drives product approvals and safety
- Supports quality-system compliance
- Hard to replicate, high value
Direct sales and service organization
Accuray Incorporated’s direct sales and service organization is a key resource because it supports customer acquisition, installation, training, and long-term uptime for its 1,000+ installed systems worldwide. In FY2025, that field team helped protect the installed base and drive recurring service demand after the initial sale.
- Specialized sales team wins new accounts.
- Service team keeps systems running.
- Installed base supports repeat revenue.
Accuray’s Core Assets Power $458.6M FY2025 Revenue
Accuray Incorporated’s key resources are its CyberKnife and Radixact/TomoTherapy platforms, plus the software, clinical know-how, and regulatory capability that keep them approved and differentiated. In FY2025, revenue was $458.6 million, supported by 1,000+ installed systems worldwide and a field team that drives sales, service, and uptime.
| Resource | Why it matters |
|---|---|
| Platforms | CyberKnife, Radixact, TomoTherapy |
| Base | 1,000+ systems; FY2025 revenue $458.6M |
Value Propositions
Precise tumor targeting
Accuray’s value lies in precise radiation delivery: CyberKnife uses robotic, image-guided therapy with sub-millimeter accuracy to target primary and metastatic tumors outside the brain. That precision helps clinicians reach hard-to-treat sites while sparing nearby healthy tissue, a key need in complex cases.
Integrated workflow
Accuray Incorporated’s integrated workflow brings planning, delivery, and data management into one system, which cuts handoffs and reduces fragmentation across treatment steps. In FY2025, the company served a global installed base across 100+ countries, and that scale makes a single workflow more valuable for care teams that need faster throughput and fewer data errors.
High patient throughput
Radixact is designed to support up to 50 patients daily, so treatment centers can push higher utilization and reduce bottlenecks in busy oncology schedules. That kind of throughput matters when every machine hour counts, because it can help spread fixed costs across more treatments.
Non-invasive treatment platform
Accuray Incorporated’s non-invasive treatment platform lets physicians deliver radiation-based tumor care without surgery, which matters for patients seeking less invasive options. In fiscal 2025, Accuray reported revenue of about $439.6 million, showing demand for systems that expand treatment choices across oncology centers.
- Radiation without surgery
- Fits less-invasive care needs
- Broadens physician options
Global service and training support
Accuray’s global service and training support lowers adoption risk for complex radiation systems by covering installation, staff training, and post-sale support. In FY2025, that matters because clinical uptime and safe use drive both treatment throughput and customer retention.
Install, support, and train after sale
Reduces risk for complex capital equipment
Supports uptime and safe clinical use
Accuray Delivers Precise Cancer Care Across 100+ Countries
Accuray’s value proposition is precise, non-invasive radiation therapy that can treat hard-to-reach tumors while sparing healthy tissue. Its integrated workflow and global service model support faster treatment, safer use, and higher machine uptime; in FY2025, Accuray reported about $439.6 million in revenue and served customers in 100+ countries.
| Metric | FY2025 |
|---|---|
| Revenue | $439.6M |
| Global reach | 100+ countries |
| Throughput | Up to 50 patients/day |
Customer Relationships
Direct enterprise sales support
Accuray uses a direct enterprise sales force to sell high-value systems like CyberKnife and TomoTherapy, so it can tailor negotiations with hospitals and treatment centers. That fits its fiscal 2025 scale, with net revenue of about $459 million, where each deal needs technical review, clinical ROI, and service terms.
Installation and onboarding
Accuray supports customers through system installation and setup, which matters for medical equipment that changes clinical workflows. In FY2025, the company reported about $471 million in revenue, and this hands-on onboarding helps lower implementation risk by speeding site readiness, training teams, and reducing early-use errors.
Training and education
Accuray uses training and education to support clinical and technical users, helping them run systems safely and plan treatments well. In FY2025, with about $459 million in revenue and a global installed base of roughly 1,000 systems, ongoing education helps customers get more use from each platform and protect long-term service demand.
Post-sale technical support
Post-sale technical support is a core relationship tool for Accuray Incorporated, because hospitals need fast service to keep systems online and protect clinical continuity. In FY2025, Accuray reported net revenue of about $458 million, and that recurring support helps defend long-term account value after installation.
- Fast service helps reduce downtime
- Uptime supports patient treatment flow
- Support strengthens repeat sales and renewals
Professional services engagement
Accuray Incorporated extends the sale with professional services, including workflow support and system optimization, so the relationship stays active after installation. That matters in fiscal 2025 because the company’s installed base keeps creating follow-on service touchpoints, which helps defend renewals and deepen account stickiness.
- Post-sale workflow support
- System optimization after deployment
- Longer customer relationship
Accuray’s Hospital Ties Run Deep
Accuray’s customer relationships are high-touch and long term: direct sales, installation help, training, and post-sale support keep hospitals tied to the platform. In fiscal 2025, net revenue was about $459 million and the installed base was roughly 1,000 systems, so service and uptime drive repeat contact.
| Driver | FY2025 |
|---|---|
| Net revenue | $459 million |
| Installed base | ~1,000 systems |
Channels
Direct sales force
Accuray Incorporated relies mainly on a dedicated direct sales force to sell its CyberKnife and Radixact systems to hospitals and specialized treatment centers, a fit for complex capital equipment that needs clinical and financial selling. In fiscal 2025, Accuray reported $446.0 million in net revenue, and this channel supports long sales cycles, installation, and training.
U.S. sales agents
In the U.S., Accuray Incorporated uses sales agents to widen market coverage and support customer acquisition, especially where a direct sales team cannot cover every account. This channel complements direct selling by adding local reach, helping the company push systems like CyberKnife and Radixact into more hospitals and clinics.
Group purchasing organizations
In the U.S., group purchasing organizations are a key procurement channel for Accuray Incorporated because more than 90% of hospitals use them to centralize buying and cut vendor review time. That lets healthcare providers compare options faster, so purchasing decisions for capital equipment like image-guided radiation systems can move more quickly.
International distributors
Accuray uses distributors outside the U.S. to sell and support systems in local markets, which helps it penetrate regions where direct coverage is less efficient. In FY2025, Accuray reported net sales of about $458 million, and this channel matters because distributor-led execution helps adapt pricing, service, and deal flow to each market.
- Expands reach beyond U.S. direct sales
- Supports local market execution
- Helps penetration across regions
International sales agents
Accuray Incorporated uses international sales agents to support non-U.S. commercialization and keep a presence in 100+ countries without full direct coverage. That channel helps the Company reach hospitals in Europe, Asia, and emerging markets while keeping fixed selling costs lower.
- Extends non-U.S. reach
- Supports local commercialization
- Lowers coverage cost
Accuray’s Global Sales Channels Power Reach and Efficiency
Accuray Incorporated sells mainly through direct teams, plus U.S. sales agents, group purchasing organizations, and overseas distributors and agents. In FY2025, the Company reported $446.0 million in net revenue and operated in 100+ countries, so channel mix is built to reach complex hospital buyers while keeping coverage costs in check.
| Channel | Role |
|---|---|
| Direct sales | Core hospital selling |
| U.S. agents and GPOs | Broader U.S. reach |
| Distributors and agents | Non-U.S. expansion |
Customer Segments
Hospitals
Hospitals are a core Accuray buyer, using CyberKnife and Radixact systems for in-house cancer care. Accuray has installed more than 1,000 systems worldwide, and large hospital networks often pair those capital purchases with service contracts to keep throughput and uptime high.
Specialized cancer centers
Specialized cancer centers are core users of Accuray Incorporated platforms because they run high-volume radiation therapy and radiosurgery programs that depend on precision, throughput, and tight workflow fit. In FY2025, Accuray reported $458.8 million in net revenue and an installed base of more than 1,000 systems worldwide, showing how these dedicated sites anchor demand for its treatment platforms.
Radiation oncology departments
Radiation oncology departments are the main clinical buyers and users for Accuray, because they judge image-guided accuracy, throughput, and patient fit before adoption. With about 20 million new cancer cases globally in 2022 and roughly half of patients needing radiation at some stage, these departments shape purchase decisions that can lift workflow and treatment quality.
Global healthcare providers
Accuray’s customer segments are global healthcare providers, with sales and service reach across North and South America, Europe, the Middle East, India, Africa, Japan, China, Australia, New Zealand, and Asia Pacific. Its installed base exceeds 1,000 systems in more than 60 countries, so regional access and procurement paths vary by market.
- Broad international hospital and cancer-center base
- Access strategy changes by region
- Large installed base: 1,000+ systems
Oncology technology buyers
Accuray Incorporated sells to oncology technology buyers, where procurement teams and capital equipment committees weigh price, service, compliance, and clinical return before approving big-ticket systems. In FY2025, this buyer group still shaped long sales cycles for platforms that can cost millions and need tight budget sign-off.
- Procurement drives final vendor choice
- Clinical ROI matters as much as price
- Service and compliance can win deals
Accuray’s Precision Cancer Tech Draws Big Hospital Buyers
Accuray Incorporated serves hospitals, standalone cancer centers, and radiation oncology departments that buy high-ticket CyberKnife and Radixact systems for precision treatment. FY2025 net revenue was $458.8 million, and the installed base topped 1,000 systems in 60+ countries, so demand stays centered on large clinical buyers with long procurement cycles.
| Segment | Why it buys | FY2025 anchor |
|---|---|---|
| Hospitals | In-house oncology | 1,000+ systems |
| Cancer centers | High-volume precision care | $458.8M revenue |
Cost Structure
Research and development
Accuray Incorporated’s research and development is a major fixed cost driver because advanced imaging and radiation platforms need steady spending on engineering, software, and clinical testing. In fiscal 2025, R&D expense was about $44 million, so the company must keep funding product upgrades even when sales soften.
Manufacturing and quality control
Manufacturing and quality control are a major cost bucket for Accuray Incorporated because its CyberKnife and TomoTherapy systems are regulated medical devices that need specialized parts, testing, and validation at every stage. In fiscal 2025, Accuray reported about $460 million of revenue, and its gross margin stayed near 30%, showing how complex production and compliance pressure unit economics.
Sales and marketing
Accuray uses a direct sales force and partner channels across the Americas, EMEA, and APAC, with commercial spend tied to selling, demos, and account management. In FY2025, that field coverage supported revenue growth but also lifted sales and marketing expense as the company pushed into more hospitals and treatment centers.
Service and support operations
Service and support operations are a recurring cost center for Accuray Incorporated, with installation, training, customer support, and professional services tied to FY2025 field labor and technical systems. Service quality matters because it protects retention and helps keep the installed base active.
- Field personnel drive ongoing cost.
- Technical support protects retention.
Regulatory and compliance costs
Accuray Incorporated faces heavy regulatory and compliance load because it sells medical devices in tightly controlled U.S. and global markets. These costs cover FDA and MDR documentation, quality systems, and post-market surveillance, and they are a fixed part of keeping the business approved to sell and support systems worldwide.
- FDA and EU compliance are mandatory.
- Documentation adds ongoing overhead.
- Post-market controls raise cash costs.
Accuray’s High-Cost Growth Engine: R&D, Compliance, and Thin Margins
Accuray Incorporated’s cost structure is dominated by R&D, manufacturing, and compliance, with FY2025 R&D at about $44 million and revenue near $460 million. Gross margin near 30% shows that regulated device production, field support, and FDA and EU quality work keep fixed costs high.
| FY2025 cost driver | Amount |
|---|---|
| R&D | ~$44M |
| Revenue | ~$460M |
| Gross margin | ~30% |
Revenue Streams
System sales
Accuray Incorporated earns system-sales revenue from CyberKnife and TomoTherapy placements, and each deal is a high-value capital purchase that can run into millions of dollars. Its installed base tops 1,000 systems worldwide, so new placements remain a core driver of fiscal 2025 revenue.
Service revenue
Accuray Incorporated’s service revenue comes from customer support, professional services, installation, and training, and it helps smooth the business when hardware orders are uneven. In fiscal 2025, recurring service work remained a meaningful share of sales, giving the Company a steadier base than product shipments alone.
Maintenance and support contracts
Accuray Incorporated’s maintenance and support contracts sit in service revenue, which was about $178 million in fiscal 2025, so they help keep cash coming in after the initial system sale. These recurring agreements support installed systems, strengthen long-term customer ties, and smooth revenue versus one-time capital equipment orders.
Software and planning solutions
Accuray’s treatment-planning and data-management software helps drive recurring revenue by supporting integrated clinical workflows around its CyberKnife and TomoTherapy systems. In FY2025, Accuray reported net revenue of $458.8 million, and software-linked sales can help lift the mix beyond one-time equipment deals.
- Planning tools support daily workflow
- Data tools help keep sites connected
- Software revenue can add recurring sales
Upgrades and parts
Accuray Incorporated’s upgrades and parts sales keep earning after the first install, as customers buy replacements, spare parts, and system upgrades over time. In FY2025, Accuray reported revenue of $458.5 million, and this installed-base support helps extend each system’s useful life while lifting recurring value.
- Supports post-sale installed base
- Drives repeat parts and upgrade demand
- Extends system value over time
Accuray’s Revenue Mix: Systems Up Front, Service for Stability
Accuray Incorporated’s revenue streams are led by system sales, plus recurring service, maintenance, software, parts, and upgrades tied to its installed base. In fiscal 2025, net revenue was $458.8 million, with service revenue about $178 million supporting steadier cash flow.
| Stream | FY2025 |
|---|---|
| Net revenue | $458.8M |
| Service revenue | $178M |
| Installed base | 1,000+ systems |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.